ObjectiveTo observe the expressions of miR-143-3p in gastric cancer cells and gastric carcinoma tissues with its clinical significance, and to analyze the target genes with enriched pathway by using bioinformatics methods.MethodsThe expressions of miR-143-3p in different differentiation gastric cancer cells and normal gastric mucosa cell line, and the expressions in gastric cancer tissues and adjacent tissues were detected by real-time fluorescent quantitative PCR. In addition, OncomiR and YM500 databases were used to analyze the expression of miR-143-3p in gastric cancer tissues compared with adjacent tissues. Furthermore, the targets of miR-143-3p were predicted by using the software of miRecords website database, and at least three software-supported target genes were chosen to analyze the enriched the signal pathways in which the target gene was involved with DAVID 6.7 software.ResultsThe expressions of miR-143-3p in the different differentiation degree of gastric cancer cells compared with normal gastric mucosa cell line were downregulated (P<0.001), and the expression of miR-143-3p in gastric cancer tissues compared with adjacent tissues was also downregulated (downregulated in 36 cases, upregulated in 18 cases, and no alteration in 4 cases). The expression of miR-143-3p in gastric cancer tissues was associated with lymph node metastasis and invasion depth (P<0.05). Bioinformatics analysis results showed that the target genes of miR-143-3p were enriched in 38 signaling pathways associated with cancer.ConclusionMiR-143-3p is a down-regulated molecular marker in gastric cancer and a potentially clinically related tumor suppressor gene, which may be involved in the cancerous phenotype in carcinogenesis and development of gastric cancer.
Esophageal cancer is a prevalent malignant tumor of the digestive tract in China, and radical surgery remains the cornerstone of its comprehensive treatment. However, multifactorial challenges such as postoperative gastrointestinal tract reconstruction, traumatic stress, and tumor-related metabolic disturbances render esophageal cancer patients highly susceptible to malnutrition. Perioperative nutritional support therapy plays a crucial role in enhancing surgical safety, improving clinical outcomes, and elevating patients' quality of life by regulating metabolic homeostasis, preserving organ function, and optimizing the immune microenvironment. This article reviews the mechanisms underlying malnutrition in esophageal cancer, methods for nutritional status assessment, and precision intervention pathways based on multi-omics evaluations. The aim is to strengthen clinicians' awareness of standardized perioperative nutritional management for esophageal cancer patients and promote its clinical implementation, thereby facilitating postoperative recovery and improving long-term quality of life.